'OLAP' (OLAparib regulatory Post-marketing surveillance)

Trial Identifier: D0817R00010
Sponsor: AstraZeneca
Start Date: February 2021
Primary Completion Date: August 2025
Study Completion Date: August 2025
Condition: Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations